Clinical Trial

A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy

Study acronym: Empassion
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to compare empasiprubart and IVIg in adult patients with MMN. The study consists of a double-blinded part A (empasiprubart, IVIg) and an open-label part B (empasiprubart). The maximum study duration for participants is up to 49 months. More information can be found here: https://clinicaltrials.argenx.com/empassion
Protocol Amendment History 3 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-21
critical Primary endpoint(s) modified 2026-05-21
notable Enrollment increased: 115 -> 154 participants 2026-05-21
Trial Details
NCT Number NCT06742190
Lead Sponsor argenx
Conditions Multifocal Motor Neuropathy (MMN), MMN
Enrollment 154 participants
Start Date 2024-12-18
Primary Completion 2026-09 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-20